Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Guangzhou Sailera Stem Cell Technology is a prominent Chinese biotechnology firm dedicated to the research, storage, and clinical application of stem cell therapies. Established in 2009 and based in Guangzhou, the company operates a large-scale regional stem cell bank and a state-of-the-art R&D center focused on mesenchymal stem cell (MSC) technologies. Its clinical pipeline includes advanced programs for knee osteoarthritis and pulmonary fibrosis, utilizing human umbilical cord-derived MSCs. Sailera also commercializes stem cell-based skincare products and provides regenerative medicine services, positioning itself as a vertically integrated leader in the Chinese regenerative medicine market. The company is recognized as a National High-tech Enterprise and plays a significant role in establishing industry standards for stem cell quality and storage in China.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Guangzhou Sailera Stem Cell Technology.